ABSTRACT
BACKGROUND: The indication of hydroxyethyl starch is currently under critical discussion and albumin 5% (ALB) has an increasing use in the operating theatre. Therefore, ALB is routinely used in neurosurgical procedures and often combined with mannitol 20% (MAN). Purpose of this in-vitro study was to determine the influence of the combination of MAN and ALB on blood coagulation and platelet function. METHODS: Twenty-two healthy volunteers were included into this study and 21 analyzed. Blood was obtained and diluted into five groups: 1) 7% dilution with MAN; 2) 10% dilution with ALB; 3) 17% dilution with isotonic balanced electrolyte solution; 4) 17% dilution with MAN+ALB; and 5) undiluted blood as control group (CON). Rotational thrombelastometry via ROTEM® (EXTEM™/FIBTEM™ Test; SABIC, Riyad, Saudi Arabia) and thrombocyte aggregometry via Multiplate® (Roche Diagnostics, Grenzach-Wyhlen, Germany) (ASPI, ADP and TRAP-test) were used to detect differences within the intervention groups and compared to the control group. RESULTS: The maximum clot firmness in the FIBTEM™ Test (SABIC) decreased under the normal range with the combination of MAN+ALB: 8 mm (5.5-11) compared to CON: 15 mm (12.5-20), P<0.05. Platelet function (ADP test) showed significant decreases for ALB: 51 AUC (40-84) and MAN+ALB: 54 AUC (41-68) compared to CON: 92 AUC (75-101), P<0.05. Except in clotting time all other EXTEM™ tests (SABIC) of MAN+ALB subgroup showed significant impairment on blood coagulation compared to the control group. CONCLUSIONS: In this in-vitro study clinically relevant dilutions of MAN+ALB showed a significant inhibition of blood coagulation and platelet function. Further in-vivo studies are necessary to confirm these results.
Subject(s)
Mannitol , Thrombelastography , Albumins , Blood Coagulation , Blood Coagulation Tests , HumansABSTRACT
OBJECTIVE: Mannitol 20% and succinylated gelatin 4% are routinely used in neurosurgical procedures. The aim of this in vitro study was to explore the influence of both agents on blood coagulation and platelet function. METHODS: Blood from 21 healthy volunteers was obtained and then diluted so as to form five groups: (1) 7% dilution with mannitol; (2) 10% dilution with gelatin; (3) 17% dilution with isotonic balanced electrolyte solution; (4) 17% dilution with mannitol+gelatin; and (5) undiluted blood. The extrinsic thrombelastometry (EXTEM) and fibrin thrombelastometry (FIBTEM) tests were examined by rotational thrombelastometry via ROTEM®, and thrombocyte aggregometry with the aspirin inhibiting- (ASPI), adenosine diphosphate- (ADP), and thrombin-activating protein (TRAP) tests performed by Multiplate. RESULTS: In the EXTEM test clot formation time, the alpha angle, and maximum clot firmness were significantly reduced by mannitol and the combination of mannitol with gelatin. The platelet function tested in the ADP test was also significantly reduced with this combination. CONCLUSION: In this in vitro study, clinically relevant dilutions of mannitol and gelatin showed a significant inhibition of whole blood coagulation and the platelet function, which could be detrimental in neurosurgical settings.
